Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Population and Public Health

University of Toronto

$75,000.00

Improving Medication Use, Health Care and Quality of Life Through Innovative Health Outcomes Research

FY 2008-09

Summary
Healthcare utilization (administrative claims) data are rich data sources to study drug safety and effectiveness. Through universal health coverage in Canada, claims data can track all medical procedures, tests and diagnoses by residents. Together with claims processed through provincial drug benefits, these data sources permit the study of how drugs are used, as well as drug effects. We outline two pilot projects that capitalize on claims data from Ontario to examine osteoporosis pharmacotherapy. First, valid estimates of the safety and effectiveness of therapeutics are required to help inform drug policy decision making. Unfortunately, results from claims-based observational studies may be biased due to incomplete information. We will use innovative methods that supplement claims data with other data sources to examine the potential benefits of these analytic strategies in improving estimates of the effectiveness of osteoporosis drugs among seniors. Second, we know that adherence to therapy for osteoporosis is suboptimal. However, little information is available regarding the patterns of drug use or the implications of gaps in adherence to osteoporosis pharmacotherapy. We will study patterns of pharmacotherapy, predictors of large gaps in treatment and implications of gaps in adherence. Results will help identify the burden of osteoporosis in the population related to suboptimal adherence, and may be used to help develop quality improvement interventions. Results from these pilot projects will help inform future innovative projects that aim to reduce the burden of illness in the population due to adverse drug effects and failure to adhere to preventive pharmacotherapy. Results will be important to guide health policy, develop quality improvement interventions, reduce health care costs, and ultimately reduce the burden of illness in the population due to adverse drug effects and suboptimal adherence to chronic pharmacotherapy.
Program
Catalyst Grant: Population and Public Health
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
176689
Name
Cadarette Suzanne M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Catalyst Grant: Population and Public Health
Projecttitle
Improving Medication Use, Health Care and Quality of Life Through Innovative Health Outcomes Research
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$75,000
Cihrequipment2
$3,475
Programname2
Catalyst Grant: Population and Public Health
Keyworddelim
Adherence; Disease Prevention; Fractures; Osteoporosis; Pharmacoepidemiology
Abstract
Healthcare utilization (administrative claims) data are rich data sources to study drug safety and effectiveness. Through universal health coverage in Canada, claims data can track all medical procedures, tests and diagnoses by residents. Together with claims processed through provincial drug benefits, these data sources permit the study of how drugs are used, as well as drug effects. We outline two pilot projects that capitalize on claims data from Ontario to examine osteoporosis pharmacotherapy. First, valid estimates of the safety and effectiveness of therapeutics are required to help inform drug policy decision making. Unfortunately, results from claims-based observational studies may be biased due to incomplete information. We will use innovative methods that supplement claims data with other data sources to examine the potential benefits of these analytic strategies in improving estimates of the effectiveness of osteoporosis drugs among seniors. Second, we know that adherence to therapy for osteoporosis is suboptimal. However, little information is available regarding the patterns of drug use or the implications of gaps in adherence to osteoporosis pharmacotherapy. We will study patterns of pharmacotherapy, predictors of large gaps in treatment and implications of gaps in adherence. Results will help identify the burden of osteoporosis in the population related to suboptimal adherence, and may be used to help develop quality improvement interventions. Results from these pilot projects will help inform future innovative projects that aim to reduce the burden of illness in the population due to adverse drug effects and failure to adhere to preventive pharmacotherapy. Results will be important to guide health policy, develop quality improvement interventions, reduce health care costs, and ultimately reduce the burden of illness in the population due to adverse drug effects and suboptimal adherence to chronic pharmacotherapy.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cadarette, Suzanne M
Approvedterm
1 an 0 mois
Cihrcontribution2
Institute of Aging~ $75,000~ $3,475~